Lonza has added new integrated capabilities in cell binding, cell separation, and bead removal to its closed, automated, and scalable platform for personalized therapy manufacturing.
Novartis has introduced its T-Charge platform at ASH 2021, which it says will serve as the foundation for various new investigational CAR-T cell therapies in its pipeline.
Biomunex Pharmaceuticals, a French company focused on the discovery and development of bi- and multi-specific antibodies, sees its BiXAb5 project receive nearly €3m (US$3.5m) in the form of a grant from the French government.
Special Edition: Reviewing the advanced therapy pipeline
Memorial Sloan Kettering (MSK) experts shared research findings in plenary talks during the American Association for Cancer Research’s (AACR) virtual meeting last week, with one talk reviewing the latest strategies for boosting the effectiveness of CAR...
Servier to work with Yposeski for the production of lentiviral vectors, as the former works to develop allogenic CAR-T cell technology for hematological therapies.
Researchers from MIT have devised a way for T cells to be engineered to carry nanoparticle ‘backpacks’ that can deliver the payload only when interacting with the target tumour cells.
CAR T developers must be involved throughout the entire supply chain says Kite Pharma, which depends on accreditation and training programmes across its network of Yescarta administration clinics.
Gilead says it is looking to make as many as 90 academic centres available to administer CAR-T Yescarta (axicabtagene ciloleucel) following its approval in the US.
Kite Pharma has submitted the first CAR-T candidate axicabtagene ciloleucel to the EMA for review and says it is evaluating manufacturing options in Europe.
Novartis and Kite Pharma have both submitted autologous leukemia candidates for review, paving the road for the first available chimeric antigen receptor (CAR) T cell therapy.
CAR-T therapy developer Kite Pharma has licensed rights to a culturing system that replicates conditions in the thymus from researchers at the University of California.
Reliance on third-party technologies is leaving T-Cell drug developers vulnerable and has driven the larger players to invest in their own platforms, say experts.
Juno Therapeutics has agreed to settle litigation with Novartis and the Trustees of the University of Pennsylvania after Juno entered into a December 2013 license agreement with St. Jude Children’s Research Hospital, which owned the patent rights.
